Stecanella, L.A.; Bitencourt, A.P.R.; Vaz, G.R.; Quarta, E.; Silva Júnior, J.O.C.; Rossi, A.
Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18β-Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer. Pharmaceutics 2021, 13, 1792.
https://doi.org/10.3390/pharmaceutics13111792
AMA Style
Stecanella LA, Bitencourt APR, Vaz GR, Quarta E, Silva Júnior JOC, Rossi A.
Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18β-Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer. Pharmaceutics. 2021; 13(11):1792.
https://doi.org/10.3390/pharmaceutics13111792
Chicago/Turabian Style
Stecanella, Luciano A., Antonio P. R. Bitencourt, Gustavo Richter Vaz, Eride Quarta, José O. C. Silva Júnior, and Alessandra Rossi.
2021. "Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18β-Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer" Pharmaceutics 13, no. 11: 1792.
https://doi.org/10.3390/pharmaceutics13111792
APA Style
Stecanella, L. A., Bitencourt, A. P. R., Vaz, G. R., Quarta, E., Silva Júnior, J. O. C., & Rossi, A.
(2021). Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18β-Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer. Pharmaceutics, 13(11), 1792.
https://doi.org/10.3390/pharmaceutics13111792